XLO - Xilio Therapeutics Inc Market Value

Corporate company logo of Xilio Therapeutics Inc (XLO)

The price action of Xilio Therapeutics, Inc. (XLO), which has a market capitalization reaching 0.05, demonstrates business resilience to economic downturns due to stable demand for oncology therapy. Management is effectively optimizing R&D expenses following partnerships with major pharma behemoths. However, potential is constrained by fierce competition in the tumor treatment market and the probability of unforeseen bodily reactions during the testing of new drugs.

Xilio Therapeutics - XLO Market Valuation (period 07/04/2022 - 11/16/2026)

Xilio Therapeutics - analytical breakdowns and key metrics (XLO)

- market price and analyst price targets:
- market capitalization statistics:
Analysis of all company metrics:Xilio XLO
Original product of xiliotx.com

Xilio Therapeutics, Inc. (XLO) creates high added value in the immuno-oncology segment through its innovative targeted cytokine activation methods. Market capitalization measures aggregate investor demand by comparing the current business value with future revenue potential. This indicator reflects the market valuation of all company shares. Analyzing the company's total market value allows for the identification of overpayment risks during rapid growth. The total market value trend demonstrates the pace of asset revaluation.

Competitor analysis

Market Value BeiGene Ltd ONC|Market Capitalization Halozyme Corp HALO|RVMD - Market Value|Market Valuation AAPG|CG Oncology Corp (CGON) - Market Value|Market Capitalization URGN|BCAX (Bicara Corp) - Market Capitalization|Market Valuation Personalis Corp (PSNL)|Market Capitalization ERAS|Market Capitalization delcath.com (DCTH)|Market Value YmAbs YMAB|AURA: Market Capitalization|Candel Therapeutics, Inc. - Market Capitalization|Accuray Inc. (ARAY) - Market Valuation|SELLAS Life Sciences Group Inc. (SLS) - Market Value|Market Value actuatetherapeutics.com (ACTU)|Market Value Citius Oncology|HURA: Market Value|Market Valuation TARA (Protara)|FATE (Fate Therapeutics Corp) - Market Value|Market Capitalization WHWK (Aadi Bioscience Inc)|TCRX - Market Valuation|CSBR: Market Valuation|XBIT - Market Capitalization|CVM: Market Capitalization|OS Therapies Inc - Market Value|RADX (radiopharmtheranostics.com) - Market Capitalization|Market Value Artiva Biotherapeutics, Inc. ARTV|Market Capitalization ANL|Market Value VERU (Veru)|Market Capitalization TPST (tempesttx.com)|Renovaro Inc. (RENB) - Market Value|MURA - Market Value|Market Capitalization Kairos Pharma KAPA|OKUR (OnKure Therapeutics) - Market Valuation|Market Value CytoMed (GDTC)|Market Value Curis|Market Value APLM|Market Value tharimmune.com (THAR)|Market Valuation Advanced Biomed ADVB|Genprex, Inc - Market Valuation|Market Value CLDI|sunshinebiopharma.com - Market Capitalization|Market Value XBIO (xeneticbio.com)|SLRX (Salarius Pharmaceuticals) - Market Valuation|PPBT - Market Capitalization|Market Value American Oncology Network Inc|BGNE (BeiGene) - Market Value|Market Valuation CKPT (Checkpoint Therapeutics, Inc)|ELEV - Market Value|Market Capitalization ICAD (iCAD Inc.)|Ikena (IKNA) - Market Value|NTBL: Market Valuation|VIRX - Market Capitalization|MorphoSys Corp (MOR) - Market Value|Market Valuation NAYA Bio|Market Value Ascentage Pharma Group